About B3B

This author has not yet filled in any details.
So far B3B has created 225 blog entries.

Steve Burrill Left Investors Waiting from Minnesota to San Francisco

Thomas Lee has written a new feature for the San Francisco Chronicle on Steve Burrill/the embezzlement fallout - the intro: "Steve Burrill loved an audience. And he found plenty of them. With his trademark pink tie and grand exhortations about the future of biotechnology, Burrill gathered awards and speaking gigs the way hobbyists collect stamps and [...]

May 11th, 2016|

AbbVie, Sanofi Throw Billions at Stemcentrx, Medivation

Ben Fidler of Xconomy gives details about how "two of the world’s biggest pharma companies took out their wallets and threw billions of dollars at two biotechs from the San Francisco Bay Area." First, Sanofi for Medivation: "Sanofi, the French pharma giant, went public with a hostile $9.3 billion cash bid for cancer drugmaker Medivation (NASDAQ: [...]

April 28th, 2016|

$185M Gift Launches UCSF Weill Institute for Neurosciences

Largest Single Donation in UCSF History Unifies Scientists, Physicians, Students in Search for New Treatments for Brain Diseases Intro from UCSF news services/Pete Farley: "In the largest-ever gift to UC San Francisco, the Weill Family Foundation and Joan and Sanford I. “Sandy” Weill have donated $185 million to establish the UCSF Weill Institute for Neurosciences, [...]

April 26th, 2016|

Janet Napolitano on the UC Cures for Alzheimer’s Disease Initiative

From UC News: "The University of California launched the UC Cures for Alzheimer’s Disease Initiative to accelerate the development of promising Alzheimer’s disease research by scientists throughout the university system. UC President Janet Napolitano says the university is already playing a critical role in the field by conducting basic research and clinical trials. [...]

April 20th, 2016|

Invitae Seeks a Faster, Cheaper Path to Diagnosing Genetic Diseases

From Danny Levine/The Bio Report: "Invitae is changing medical practice by brining genetic testing into the mainstream. The company says it seeks to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company recently announced new [...]

April 9th, 2016|

23andMe CEO Anne Wojcicki Talks Health Care, Theranos, and…

23andMe CEO Anne Wojcicki Talks Health Care, Theranos, and Dating A-Rod on ‘Re/code Decode’ "Anne Wojcicki does not lead a quiet life: Since 2006, she’s been the CEO of prominent genomics company 23andMe. She used to be married to Google co-founder Sergey Brin. And recently, she’s been in the tabloids for dating someone who’s even [...]

April 4th, 2016|

Big3Deal: Gilead and Nimbus

SFBay-area based Gilead Sciences has acquired Nimbus Apollo, Inc., a wholly-owned subsidiary of Cambridge, MA-based Nimbus Therapeutics, and its Acetyl-CoA Carboxylase (ACC) inhibitor program to treat nonalcoholic steatohepatitis (NASH) and possibly liver cancer and other diseases. Coverage of the deal: FierceBiotech: Gilead bags early-stage NASH drug in $1.2B Nimbus deal "Gilead is anteing up a $400 million up [...]

April 4th, 2016|

How Much Could Medivation Sell For?

Medivation shares surged Thursday on rumors that potential buyers are seeking to acquire the company - some excerpts of coverage: FierceBiotech: Step right up and place your bets on who might buy Medivation "AstraZeneca ($AZN), Roche ($RHHBY) and Sanofi ($SNY) are just three Big Pharma names being touted as a possible suitor for the struggling biotech Medivation ($MDVN)--but [...]

March 31st, 2016|